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Xuenan Chang3 and Enyou Li1*Abstract
Introduction: There are approximately 19 million new cases of sepsis worldwide each year. Among them, more
than one quarter of patients die. We aimed to assess the effects of heparin on short-term mortality in adult patients
with sepsis and severe sepsis.
Methods: We searched electronic databases (Medline, Embase, and Cochrane Library databases; the Cochrane
Controlled Trials Register) and conference proceedings (Web of Knowledge (Conference Proceedings Citation
Index - Science, Conference Proceedings Citation Index - Social Sciences & Humanities)) from inception to July
2014, expert contacts and relevant websites. Controlled trials of heparin versus placebo in sepsis or severe sepsis
were identified. In total two reviewers independently assessed eligibility, and four authors independently extracted
data; consensus was reached by conference. We used the chi-square test and I2 to assess statistical heterogeneity
(P <0.05). The primary analysis was based on the fixed-effect model to produce pooled odds ratios with 95%
confidence intervals.
Results: A total of nine publications were included in the meta-analysis. Heparin decreased 28-day mortality (n = 3,482,
OR = 0.656, 95% CI = 0.562 to 0.765, P <0.0001). According to the meta-analysis of 28-day mortality, heterogeneity was
not found among the eight randomized clinical trials (RCTs) (I2 = 0.0%). Heparin had no effect on bleeding events in
sepsis (seven RCTs, n = 2,726; OR = 1.063; 95% CI = 0.834 to 1.355; P = 0.623; and I2 = 20.9%). Subgroup analysis
demonstrated that the sample size may be a source of heterogeneity, but experimental design was not.
Conclusions: Heparin may reduce 28-day mortality in patients with severe sepsis, at the same time, there was no
increase in the risk of bleeding in the heparin group. We recommend the use of heparin for sepsis and severe sepsis.Introduction
There are approximately 19 million new cases of sepsis
worldwide each year. Among them, more than one quar-
ter of patients die. In addition, there is an upward trend
in sepsis incidence; sepsis and septic shock have become
serious health problems [1,2]. Heparin was first applied
in the treatment of sepsis in 1966. By evaluating a novel
therapeutic concept in clinical practice, Martinez et al.* Correspondence: enyouli@aliyun.com
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related to the use of heparin, steroids, and vasoactive
drugs [3], which inspired many researchers to evaluate
heparin for sepsis treatment. Therefore, many clinical
studies have been conducted since that first report. Cur-
rently, the efficacy and safety of heparin in sepsis patients
remain controversial, with some authors suggesting that
heparin may reduce 28-day mortality [4,5] and others
reporting no effect on 28-day mortality [6-9]. We con-
ducted a meta-analysis of studies on heparin treatment for
sepsis to evaluate the effect of heparin on 28-day mortality
and the occurrence of bleeding events in patients with
sepsis.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Search strategy for identification of studies
We conducted a systematic review and several meta-
analyses of the existing literature according to the
methods recommended in the PRISMA statement for
reporting systematic reviews and meta-analyses of stud-
ies that evaluate healthcare interventions (Figure 1). No
institutional review board (IRB) approval or consents
were needed for this systematic review because it evalu-
ated published studies.
Our investigators were divided into four groups. CW
was primarily responsible for the literature search group
(CW and LG). JS and XW were responsible for the two
literature review groups (JS, XW, LG, and XC). The tri-
als were identified by electronic and manual searches.
The electronic searches were performed by two authors
(CW and LG) who independently searched the Medline,
Embase, and Cochrane Library databases, the CochraneFigure 1 Flow diagram of the literature search.Central Register of Controlled Trials, and Web of Know-
ledge (Conference Proceedings Citation Index - Science,
Conference Proceedings Citation Index - Social Sciences
& Humanities). We did not restrict our search based on
language or year of publication. The last search update
was July 2014. Additionally, we manually searched the
Index Medicus of randomized clinical trials (RCTs), meta-
analyses, and systematic reviews for studies that were
missed in the initial electronic search. The search strategy
identified 1,738 studies. Two literature review groups con-
ducted the literature exclusion; 66 studies were included
for potential interest.
Inclusion and exclusion criteria
The literature inclusion and exclusion procedures were
performed independently by two literature review groups
(XW and XC; LG and EL). We excluded review, retro-
spective analyses, repeated literature reports, and repeated
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in different literature reports); purely physiological studies
(for example, Effect of recombinant activated protein C and
low-dose heparin on neutrophil-endothelial cell interactions
in septic shock [10]); imaging studies; pediatric studies;
studies on medications other than heparin; and studies
without a control group (see Table S1 in Additional file 1).
If data were missing, the literature search group contacted
the authors for the relevant data. Subsequently, the two
study review groups performed the initial verification.
A disagreement occurred for two studies [5,9], which
were eventually excluded after a discussion among all
of the authors.
Study selection and data abstraction
The data extraction strategy was discussed and designed
by two authors (CW and CC). After all of the authors
had discussed and reviewed the strategy, the correspond-
ing author approved the final version of the study design
strategy. The process yielded nine published studies.
Two groups of researchers independently conducted a
second round of data extraction from the literature. Key
data were 28-day mortality and bleeding events. If the
relevant data were missing or ambiguous, we contacted
the authors for clarification. After the two separate lit-
erature review groups conducted the data extraction, the
data were verified. If there was an inconsistency, the data
extraction was repeated until a consensus was reached.
Quality assessment
Quality assessments were performed separately by the two
literature review groups. Studies that received inconsistent
scores were scored again by all of the authors. The quality
of the RCT studies was assessed using a modified Jadad
scale [11], in which the generation of random sequences,
blinding method, and reasons for withdrawal and dropout
at the time of follow-up were evaluated. A seven-point
scale was used, with one to three indicating a low-quality
study and four to seven indicating a high-quality study.
For non-randomized controlled trial (NRCT) studies, the
data were extracted from subgroup analysis, and we used
Silber’s quality assessment, which is a new score for sub-
group analyses from randomized controlled trials [12] that
includes prospectively collected data, subgroup analysis
from a randomized controlled trial, multicenter trials
(at least three centers), data from clinical events com-
mittees/data safety monitoring boards independent of
steering committee monitoring (≥10%) and follow-up
percentage. The maximum possible Silber score is five.
Analyses
CC was responsible for the data analysis group (CC and
JZ). The outcomes of the meta-analysis included 28-day
mortality and bleeding events in patients with sepsiswho were treated with heparin. After the extracted data
were reviewed and verified by different study groups,
Stata software (Version 12.0; StataCorp LP, College
Station, TX, USA) was used for statistical analysis. The
Cochrane Handbook of Systematic Reviews notes that
the most commonly encountered effect measures used
in clinical trials with dichotomous data are odds ratio
(OR) and relative risk (RR). Both are entirely valid ways
of describing a treatment. At the same time, because the
mortality was calculated over different time points in
most study designs, the hazard ratio (HR) is a more
appropriate parameter for mortality calculations [13].
However, the HR may suffer relatively greater bias due
to internal variability in different studies. As the value of
the HR is considered closer to the OR, the authors chose
ORs and 95% confidence intervals (CIs) as approximate
parameters to evaluate the effect of heparin on 28-day
mortality and bleeding events in septic patients [14,15].
Between-study heterogeneity was assessed using an I2
statistic (25% is defined as low heterogeneity, 50% as
moderate heterogeneity, and 75% as high heterogeneity;
significant heterogeneity is considered if I2 is greater
than 50%) [16]. The fixed-effect model was applied if no
or low significant heterogeneity was present, and pooled
ORs were estimated using the Mantel-Haenszel method
[17]. We performed a Z significance test on pooled ORs.
Subgroup analysis was performed on bleeding events ac-
cording to the sample size (that is, <100 or >100) and
randomization method (that is, NRCT or RCT) of each
study. We also assessed publication bias and small study
bias. The Egger test was usually applied for continuous
data analysis. However, the response variables of this
study were dichotomous variables. Therefore, the publica-
tion bias was quantitatively examined using the Harbord
test [18]. All statistical analyses are two-tailed tests. All
hypotheses were tested at the alpha = 0.05 level.
Results
Whether lower quality articles should be included in
meta-analysis is still controversial [19]. Some think that
the low scores do not mean low quality, and the study
may be standard and have no bias [20]. In other words,
the research process may strictly regulate, but the paper
is not standardized [21]. In an empirical study of the
relation of quality scores to treatment differences in
published meta-analysis of seven groups of controlled
randomized clinical trials comprising 107 primary stud-
ies, Emerson et al. found no relation between treatment
difference and overall quality score [22]. For the above
reasons and PRISMA principles, we analyzed the data
including and ruling out low-quality articles, and we
found that after removing the low-quality articles, they
had no effect on the results. Because the more studies
integrated into the article, the greater the sample size,
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analysis of all of the studies. In addition, the analysis of the
high-quality studies is in Table S2 in Additional file 1.
Nine studies (Table 1) were included in the meta-
analysis [4,7,8,23-28]. Except for a lack of 28-day mortality
data in Yang et al.’s study [27], the remaining eight studies
all performed analyses of 28-day mortality. Additionally,
Liu et al.’s study [28] had no bleeding events data. Raw
data were directly provided in eight [4,7,8,23-25,27,28] of
the nine studies. The data from one study [26] were ob-
tained indirectly from the corresponding authors [29].
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Twenty-eight-day mortality analysis
We performed analyses for eight studies [4,7,8,23-26,28],
which included 3,482 participants (2,378 participants
were included in the patient group and 1,104 partici-
pants in the control group). Within 28 days of admis-
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CI = 0.562 to 0.765; P <0.0001; I2 = 0.0%), indicating a
statistically significant reduction in 28-day mortality
in heparin-treated patients with sepsis (see Table S3 in
Additional file 1 and Additional file 2). There was no
evidence of between-study heterogeneity (I2 = 0.0%),
and a sensitivity analysis was not performed.
Subgroup analysis
Subgroup analysis was performed according to the dif-
ferent experimental designs of the eight studies. The in-
cluded studies were divided into two subgroups: an
NRCT group and an RCT group. For the three NRCT
studies, OR = 0.648, 95% CI = 0.550 to 0.764, P <0.001,
and I2 = 6.7%. For the five RCT studies, OR = 0.717, 95%
CI = 0.458 to 1.122, P = 0.145, and I2 = 0.0%. Subgroup
analysis indicated that the results of the NRCT group
reached statistical significance. Although the results
from the RCT group are not statistically significant, the
high value of the 95% CIs (1.122) is very close to the
invalid line. When heterogeneity was assessed in the
different subgroups, there was either low-level or no
heterogeneity (see Table S3 in Additional file 1 and
Additional file 3).
Subgroup analysis was also performed according to
sepsis severity. For the four studies on severe sepsis
(defined as sepsis complicated by organ dysfunction and
tissue hypoperfusion), OR = 0.650, 95% CI = 0.552 to
0.766, P <0.001, and I2 = 0%. For the four studies on
non-severe sepsis, OR = 0.702, 95% CI = 0.4443 to
1.115, P = 0.134, and I2 = 0.0%. Heparin may have thera-
peutic effects in patients with severe sepsis, but it has no
effect on patients with non-severe sepsis. Similar to the
subgroup analysis of the different experimental designs,
the high 95% CIs from the sepsis group were also veryFigure 2 Subgroup analysis of 28-day mortality according to sepsis sclose to the invalid line (see Figure 2 and Table S3 in
Additional file 1).
Publication bias analysis
We also analyzed publication bias for 28-day mortality
in the included studies. Because the response variables
were dichotomous, publication bias was quantitatively
examined using the Harbord test. The P value was 0.881
in the 28-day mortality analysis, indicating that there was
no evidence of publication bias in these studies (see Table
S3 in Additional file 1 and Additional file 4).
The bleeding events analysis
We performed a statistical analysis on seven studies
[4,7,8,23-25,27] that included 2,726 participants (1,775
participants in the patient group and 951 participants in
the control group). There were 251 (14.14%) bleeding
events in the patient group and 112 (11.78%) in the con-
trol group (OR = 1.063; 95% CI = 0.834 to 1.355; P =
0.623; I2 = 20.9%). The results failed to reach statistical sig-
nificance, indicating that heparin has no effect on bleeding
events in patients with sepsis (see Figure 3 and Table S3 in
Additional file 1).
There was a low level of heterogeneity between stud-
ies, and a sensitivity analysis was not performed.
Subgroup analysis
To investigate whether the bleeding events were associ-
ated with sepsis severity, we conducted a subgroup ana-
lysis according to sepsis severity. For the severe sepsis
group, OR = 1.076, 95% CI = 0.836 to 1.384, P = 0.569,
I2 = 34.9%; for the sepsis group, OR = 0.897, 95% CI =
0.354 to 2.275, P = 0.819, I2 = 35.1%. The statistical re-
sults did not show that bleeding events were related to
sepsis severity (see Table S3 in Additional file 1 andeverity (the severe sepsis group).
Figure 3 Bleeding events.
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investigate the effects of different subgroups on hetero-
geneity. The included studies were divided into two sub-
groups: an NRCT group and an RCT group. For the two
NRCT studies, OR = 1.045, 95% CI = 0.802 to 1.362,
P = 0.745, I2 = 7.4%. For the four RCT studies (Zhang
et al. [7] was automatically excluded), OR = 1.524, 95%
CI = 0.369 to 6.292, P = 0.561, and I2 = 43.4%. Four
studies with sample sizes over 100 were included in this
subgroup with an OR = 1.018, 95% CI = 0.796 to 1.302,
P = 0.887, and I2 = 1.0%. Two studies (Zhang et al. [7]
was automatically excluded) were included in the subgroup
with sample sizes less than 100 with an OR = 7.497, 95%
CI = 0.885 to 63.529, P = 0.065, I2 = 0.0%. (see Table S3 in
Additional file 1, Additional file 6 and Additional file 7).
Heterogeneity decreased in the NRCT subgroup, while
heterogeneity increased in the sample size and RCT sub-
groups, compared with overall heterogeneity. Therefore,
sample size may be a source of heterogeneity.
Publication bias analysis
The P value was 0.343 in the bleeding events analysis
(see Table S3 in Additional file 1 and Additional file 8).
Discussion
This study revealed that heparin can significantly reduce
28-day mortality in patients with severe sepsis but that it
has no effect on the occurrence of bleeding events.
During the process of the analysis, two researchers
independently extracted the data. If the study data were
inconsistent, we re-collected the data after discussion.
We also contacted the corresponding authors to obtaindetailed information or to confirm some key data regarding
experimental results. This study design can reduce ascer-
tainment bias [30].
Of the nine articles, heparin was the objective drug in
six studies. Although the effects of heparin were not the
objectives of three original articles, heparin was not a
concomitant medication in our extracted data. The three
original studies were large, multicenter RCTs [24-26] of
antithrombin III (randomized to the ‘antithrombin III
group’, ‘placebo group’), tissue factor pathway inhibitor
(TFPI) (randomized to the ‘drotrecogin alfa (activated)
group’, ‘placebo group’), and recombinant human acti-
vated protein C (randomized to the ‘tifacogin group’,
‘placebo group’) for the treatment of severe sepsis. Hep-
arin was used in all of these large RCT studies; however,
it was only used as a concomitant medication. The au-
thors did not evaluate the efficacy of heparin on sepsis
treatment separately. In the above three studies, the au-
thor lists the proportion of patients using heparin in the
‘experimental group’ and the ‘placebo group’. When we
extracted the data from the above three studies, with ref-
erence to Agarwal et al.’s method [29], the patients who
received heparin in the ‘placebo group’ were treated as
the study group, and the patients in the ‘placebo group’
who did not receive heparin were treated as the control
group. Only data from a blank group were extracted for
analysis to eliminate the interference of other anticoagu-
lants. Both Levi et al.’s study [5] and Iba et al.’s study [9]
investigated heparin treatment for sepsis. In addition to
heparin, the patients also received drotrecogin alfa (acti-
vated) (Drot AA) or antithrombin, respectively. In con-
trast with the Warren et al. [24], Abraham et al. [25],
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tract data about the blank group without other anti-
coagulants. The studies indicated that Drot AA has
antithrombotic and profibrinolytic properties, which can
provide adequate prevention from venous thromboembol-
ism itself. However, Drot AA can potentially weaken the
preventive effect of heparin in sepsis treatment [5,26],
which may affect the study results. Therefore, after
discussion, we did not include these studies in the
analysis.
Agarwal et al. [29] applied RevMan statistical soft-
ware to perform a simple meta-analysis on the Warren
et al. [24], Abraham et al. [25], and Bernard et al. [26]
studies to investigate the efficacy of heparin therapy
for patients with sepsis. The study result was relatively
consistent with our study, suggesting that heparin can
significantly reduce 28-day mortality in patients with
severe sepsis. In contrast with Agarwal et al.’s study,
we included four additional studies that described
RCTs evaluating heparin treatment. More importantly,
we included a new study conducted in 2009 [23],
which was considered the first heparin RCT with a
large sample size and a blank control. Therefore, the
inclusion of this study undoubtedly improved the reli-
ability of the meta-analysis as it played a prominent
role in the study analysis. In addition, Agarwal et al.’s
study did not perform a meta-analysis on the effect of
heparin on the occurrence of bleeding events. How-
ever, we performed a meta-analysis of seven studies
and found that heparin has no effect on bleeding
events in patients with sepsis. The reason may be that
the low dose of heparin in the original articles leads to
no increase in the risk of bleeding in patients treated
with heparin.
In this study, we found that heparin can reduce 28-
day mortality in patients with severe sepsis; however, it
had no effect on 28-day mortality in patients with non-
severe sepsis. A meta-analysis of heparin therapy in med-
ically critical surgical patients [31] revealed that heparin
can effectively prevent deep vein thrombosis (DVT) with-
out increasing the risk of bleeding. The latest published
Surviving Sepsis Campaign (SSC) [2] guideline also rec-
ommends the use of heparin as part of DVT prophylaxis
for severe sepsis. The results of this study showed that
heparin reduced 28-day mortality in patients with severe
sepsis. The possible explanations are as follows: 1. As an
anticoagulant, heparin effectively reduces the occurrence
of deep venous thromboembolism in patients with severe
sepsis. 2. The occurrence and development of sepsis are
closely related to inflammation and the coagulation system
[6,32]. The interaction between coagulation activation and
the inflammatory response is the characteristic patho-
logical process of sepsis [33,34]. As an anticoagulant,
heparin also has an anti-inflammatory effect: it can reducethe blood levels of inflammatory mediators (such as
histamine) and can increase the release of TFPIs [35].
Heparin plays an anti-inflammatory role in the patho-
physiology of severe sepsis [36].
This study also has limitations. The New England Jour-
nal of Medicine published a study of multicenter, ran-
domized placebo-controlled studies in 2011 [37] that
showed no differences in the prevention of DVT be-
tween unfractionated heparin and low-molecular-weight
heparin. However, a meta-analysis by Alhazzani et al.
[31] revealed that low-molecular-weight heparin can
prevent thrombosis better than unfractionated heparin.
Low-molecular-weight heparin can also effectively re-
duce the incidence of DVT. Moreover, studies have re-
vealed different anticoagulant mechanisms for thrombin
inhibition between unfractionated heparin and low-
molecular-weight heparin [38].We attempted to perform
a subgroup analysis on the two types of heparin. How-
ever, because the existing studies of heparin therapy, ex-
cept for the XPRESS study [5], did not differentiate the
two types, our study could not compare the effectiveness
of the different types of heparin treatment for patients
with sepsis. In NRCT studies [24-26], heparin was ad-
ministered to some patients and not to others at the
discretion of the treating physician. This confounding
factor may have an effect on the results of the meta-
analysis. After careful observation, we found that the
95% CIs of the RCT and sepsis groups were very close to
the invalid lines in the subgroup analysis of 28-day
mortality, meaning that there is a trend of decreased
short-term mortality in patients who used heparin. Large-
sample-size, multicenter, double-blind, parallel-group trials
are needed to validate whether heparin can significantly re-
duce 28-day mortality.
Conclusions
In conclusion, heparin may reduce 28-day mortality in
patients with severe sepsis because there was a trend
of decreased short-term mortality in patients who
used heparin. At the same time, there was no increase
in the risk of bleeding in the heparin group. We
recommend the use of heparin for sepsis and severe
sepsis.
Key messages
 In adults, the efficacy of heparin for sepsis has not
been well established.
 This meta-analysis evaluated the short-term effects
of heparin on sepsis mortality. Pooled data showed
that heparin may decrease 28-day mortality and
longer-term mortality.
 The use of heparin for sepsis is safe with no increase
in the risk of bleeding.
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